HK1212683A1 - 多个激酶途径抑制剂 - Google Patents

多个激酶途径抑制剂 Download PDF

Info

Publication number
HK1212683A1
HK1212683A1 HK16100505.0A HK16100505A HK1212683A1 HK 1212683 A1 HK1212683 A1 HK 1212683A1 HK 16100505 A HK16100505 A HK 16100505A HK 1212683 A1 HK1212683 A1 HK 1212683A1
Authority
HK
Hong Kong
Prior art keywords
pathway inhibitors
kinase pathway
multiple kinase
kinase
inhibitors
Prior art date
Application number
HK16100505.0A
Other languages
English (en)
Chinese (zh)
Inventor
Qingping Zeng
Mary Faris
Alexis MOLLARD
Steven L. Warner
Gary A. Flynn
Original Assignee
Mannkind Corporation
Tolero Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corporation, Tolero Pharmaceuticals, Inc. filed Critical Mannkind Corporation
Publication of HK1212683A1 publication Critical patent/HK1212683A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16100505.0A 2012-09-26 2013-09-25 多个激酶途径抑制剂 HK1212683A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261706084P 2012-09-26 2012-09-26
US61/706,084 2012-09-26
US201361757331P 2013-01-28 2013-01-28
US61/757,331 2013-01-28
US201361785992P 2013-03-14 2013-03-14
US61/785,992 2013-03-14
PCT/US2013/061548 WO2014052365A1 (en) 2012-09-26 2013-09-25 Multiple kinase pathway inhibitors

Publications (1)

Publication Number Publication Date
HK1212683A1 true HK1212683A1 (zh) 2016-06-17

Family

ID=50388917

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100505.0A HK1212683A1 (zh) 2012-09-26 2013-09-25 多个激酶途径抑制剂

Country Status (8)

Country Link
US (2) US9493454B2 (cg-RX-API-DMAC7.html)
EP (1) EP2900668A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015532281A (cg-RX-API-DMAC7.html)
CN (1) CN104812756A (cg-RX-API-DMAC7.html)
AU (1) AU2013323736A1 (cg-RX-API-DMAC7.html)
CA (1) CA2886275A1 (cg-RX-API-DMAC7.html)
HK (1) HK1212683A1 (cg-RX-API-DMAC7.html)
WO (1) WO2014052365A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
AU2013323736A1 (en) * 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors
MX394360B (es) 2013-03-14 2025-03-24 Sumitomo Pharma Oncology Inc Inhibidores de jak2 y alk2 y metodos para su uso.
CN104418853B (zh) * 2013-08-28 2016-09-07 北大方正集团有限公司 取代的萘啶-2-酮化合物、制备方法、用途及药物组合物
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016161248A1 (en) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
KR102608921B1 (ko) 2015-05-18 2023-12-01 스미토모 파마 온콜로지, 인크. 생체 이용률이 증가된 알보시딥 프로드러그
JP7083497B2 (ja) 2015-08-03 2022-06-13 スミトモ ファーマ オンコロジー， インコーポレイテッド がんの処置のための併用療法
CN105130986B (zh) * 2015-09-30 2017-07-18 广州科擎新药开发有限公司 嘧啶或吡啶并吡啶酮类化合物及其应用
WO2018094275A1 (en) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
TWI749126B (zh) * 2016-12-16 2021-12-11 大陸商基石藥業（蘇州）有限公司 Cdk4/6抑制劑
CN108264511B (zh) * 2017-01-03 2021-04-13 浙江海正药业股份有限公司 杂环类衍生物及其制备方法和其在医药上的用途
WO2018213219A1 (en) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones and related compounds as inhibitors of protein kinases
JP7196160B2 (ja) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン
KR20210003780A (ko) 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
JP2021521170A (ja) 2018-04-13 2021-08-26 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 骨髄増殖性新生物およびがんに関連する線維症の処置のためのｐｉｍキナーゼ阻害剤
AU2019310590A1 (en) 2018-07-26 2021-01-14 Sumitomo Pharma Oncology, Inc. Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
US11034710B2 (en) 2018-12-04 2021-06-15 Sumitomo Dainippon Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
CA3120850A1 (en) * 2018-12-07 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Methods for treating castration-resistant and castration- sensitive prostate cancer
KR20260008165A (ko) 2019-02-12 2026-01-15 스미토모 파마 아메리카, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
WO2020191326A1 (en) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Treatment of acute myeloid leukemia (aml) with venetoclax failure
CN117430597A (zh) * 2022-07-14 2024-01-23 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6150359A (en) * 1997-08-20 2000-11-21 Warner-Lambert Company Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
AU2004279427B2 (en) * 2003-10-08 2008-07-03 Irm Llc Compounds and compositions as protein kinase inhibitors
MX2008014618A (es) * 2006-05-15 2008-11-28 Irm Llc Composiciones y metodos para inhibidores de cinasas del receptor fgf.
WO2007136790A2 (en) 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
AU2013323736A1 (en) * 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors

Also Published As

Publication number Publication date
US20170107215A1 (en) 2017-04-20
CA2886275A1 (en) 2014-04-03
JP2015532281A (ja) 2015-11-09
AU2013323736A8 (en) 2015-04-30
US9493454B2 (en) 2016-11-15
WO2014052365A1 (en) 2014-04-03
EP2900668A4 (en) 2016-04-20
CN104812756A (zh) 2015-07-29
US9714247B2 (en) 2017-07-25
AU2013323736A1 (en) 2015-04-09
EP2900668A1 (en) 2015-08-05
US20150266870A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
HK1212683A1 (zh) 多个激酶途径抑制剂
HK1202377A1 (en) Modulating certain tyrosine kinases
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
EP3091008A4 (en) Kinase inhibitor and use thereof
IL238571A0 (en) Broton tyrosine kinase inhibitors, preparations containing them and their uses
WO2016123054A3 (en) Kinase drug combinations and methods of use thereof
EP3060173A4 (en) Methods and systems for heart valve therapy
WO2012158843A3 (en) Kinase inhibitors
EP3035800A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
SI2857404T1 (sl) Imidazo(1,2-b)piridazin derivati kot kinazni inhibitorji
SMT201700414T1 (it) Inibitori indazolici della via di segnale di wnt e loro usi terapeutici
PT2955185T (pt) Inibidores da atividade de cinase de pirazole substituído policíclico e sua utilização
EP2683243A4 (en) PI3 KINASE INHIBITORS AND USES THEREOF
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
IL235938A0 (en) Pyrimidinyls are tyrosine kinase inhibitors
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
IL235418A0 (en) Biologically active projectiles, systems, and methods
ZA201406777B (en) 3,5-diaminopyrazole kinase inhibitors
IL239904A0 (en) Inhibitory oligonucleotides and their use in therapy
EP3068389A4 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
EP3113776A4 (en) Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
EP2968995A4 (en) INHIBITORS OF LRRK2 KINASE ACTIVITY
EP3068378A4 (en) Random copolymer therapeutic agent carriers and assemblies thereof
EP2900243A4 (en) BICYCLIC OXA LACTAM KINASE HEMMER